The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived

Robert Weissert
  • Expert Review of Neurotherapeutics, November 2006, Taylor & Francis
  • DOI: 10.1586/14737175.6.11.1587

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1586/14737175.6.11.1587

The following have contributed to this page: Professor Robert Weissert